You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.

With a commercial presence in 100 countries, we operate through a fully integrated business model from the collection of plasma in our own centers in the United States, Hungary and Germany to fractionation and production in our manufacturing facilities located in Italy, Hungary and the United States.

PRESS RELEASES

Results as of 30 September 2018

Consolidated turnover of Euro 438.6 million and adjusted EBITDA of Euro 104.8 million

read more 

First half results 2018

Consolidated turnover of Euro 278.3 million and adjusted gross margin of 39.0%

read more 

Updated Bylaws

Kedrion’s Extraordinary Meeting of Shareholders approves the amendment of the Company’s Bylaws

read more 

Financial reports

About Kedrion - Front Image

    CONSOLIDATED FIRST HALF RESULTS 2018

    Consolidated Financial Statements 2017

    Consolidated First Half Results 2017

    Consolidated Financial Statements 2016

    Consolidated Financial Statements 2015

KEDRION NOTES

Contact & Email alerts

Subscribe to the service in order to receive our news

For more information please contact: investor@kedrion.com